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Objectives The aim of this study was to evaluate the safety, tolerability, and effects of AMG 145 on low-density lipoprotein
cholesterol (LDL-C) in healthy and hypercholesterolemic subjects on statin therapy.
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) down-regulates surface expression of the low-density lipo-
protein receptor (LDL-R), increasing serum LDL-C. AMG 145, a fully human monoclonal antibody to PCSK9, pre-
vents PCSK9/LDL-R interaction, restoring LDL-R recycling.
Methods Healthy adults (phase 1a) were randomized to 1 dose of AMG 145: 7, 21, 70, 210, or 420 mg SC; 21 or 420 mg
IV; or matching placebo. Hypercholesterolemic adults (phase 1b) receiving low- to moderate-dose statins were
randomized to multiple SC doses of AMG 145: 14 or 35 mg once weekly (QW) 6, 140 or 280 mg every
2 weeks (Q2W) 3, 420 mg every 4 weeks 2, or matching placebo. Eleven subjects receiving high-dose st-
atins and 6 subjects with heterozygous familial hypercholesterolemia were randomized to SC AMG 145 140 mg
or placebo Q2W 3.
Results In the trials (AMG 145 n  85, placebo n  28), AMG 145 reduced LDL-C up to 64% (p  0.0001) versus pla-
cebo after 1 dose 21 mg and up to 81% (p  0.001) with repeated doses 35 mg QW. No serious adverse
events (AEs) occurred. Overall incidence of treatment-emergent AEs was similar in AMG 145 versus placebo
groups: 69% versus 71% (phase 1a); 65% versus 64% (phase 1b).
Conclusions In phase 1 studies, AMG 145 significantly reduced serum LDL-C in healthy and hypercholesterolemic statin-
treated subjects, including those with heterozygous familial hypercholesterolemia or taking the highest doses of
atorvastatin or rosuvastatin, with an overall AE profile similar to placebo. (J Am Coll Cardiol 2012;60:1888–98)
© 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.08.986Low-density lipoprotein cholesterol (LDL-C) reduction
(especially with statins) is the cornerstone of therapeutic
efforts to reduce the risks of both first and subsequent
cardiovascular events (1,2). Serum LDL-C levels are pre-
dominantly influenced by clearance of apolipoprotein B
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November 6, 2012:1888–98 AMG 145 Effects on LDL-C, Safety, and Tolerabilityplasma LDL-C and the risk of cardiovascular disease (7,8),
whereas PCSK9 loss-of-function mutations reduce plasma
LDL-C levels and cardiovascular risk (9,10). Several studies
indicate that statins increase PCSK9 levels (11–14), suggesting
hat a PCSK9 antagonist might further reduce LDL-C levels in
atients receiving statins.
AMG 145 is a fully human monoclonal antibody (im-
unoglobulin G2) that binds specifically to human PCSK9,
reventing its interaction with the LDL-R and thereby
estoring LDL-R recycling and LDL-C uptake (15). We
eport results from 2 randomized, double-blind, placebo-
ontrolled, ascending-dose phase 1 studies of AMG 145 in
ealthy adults and in subjects with hypercholesterolemia
eceiving stable doses of statins.
ethods
ubjects. The phase 1a study enrolled healthy subjects
7 cohorts); the phase 1b study enrolled hypercholester-
lemic subjects receiving stable statin therapy (7 cohorts: 5
eceiving low- to moderate-dose statins, 1 receiving high-
ose statin therapy, and 1 with heterozygous familial hy-
ercholesterolemia (HeFH) (score 9, World Health Or-
anization criteria [16]) (Fig. 1).
The protocol and study procedures were approved by an
nstitutional review board. All subjects provided written
nformed consent before study procedures were performed.
tudy design and treatment. In the phase 1a study,
ligible subjects at 1 U.S. center were randomized (1
lacebo/3 AMG 145) to a single dose of placebo or AMG
45, 7 mg to 420 mg administered SC or 21 mg or 420 mg
dministered IV in a 1-h infusion (Fig. 1A). In the phase 1b
tudy, conducted at 10 U.S. centers, subjects receiving low-
o moderate-dose statins were randomized 1:3 to subcuta-
eous placebo or AMG 145 and sequentially assigned to 1
f 5 dose-escalation cohorts (14 mg QW  6 doses to 420
g Q4W  2 doses) (Fig. 1B). The high-dose statin and
HeFH cohorts received 140 mg SC Q2W  3 doses or
placebo.
Endpoints and assessments. In both studies, the primary
endpoint was the safety and tolerability of AMG 145;
secondary endpoints included effects of AMG 145 on serum
LDL-C (measured by a homogeneous direct assay). Addi-
tional lipid parameters, free PCSK9, Apo-B, and lipopro-
tein (Lp)(a) levels were also measured. On-study treatment-
emergent and treatment-related adverse events (AEs) were
reported; treatment-related AEs were those that the inves-
tigator felt might have been caused by the investigational
product.
Methods used for safety and efficacy assessments are
described in the Online Appendix.
Statistical analyses. Safety analyses included all subjects
who received 1 dose of AMG 145 or placebo. The
analyses of the effects of AMG 145 on lipids included all
subjects who received investigational product and had 1
post-baseline value. Descriptive statistics were used fordemographic, safety, and efficacy
data. All placebo subjects were
pooled in the phase 1a study. In
the phase 1b study, all placebo
subjects were pooled for safety
analyses; for lipid analyses, pla-
cebo subjects were pooled for
dose-escalation cohorts and ana-
lyzed separately for the high-
dose statin and HeFH cohorts.
As pre-specified, the ratio of
LDL-C and other lipids to base-
line at various time points was
log-transformed and analyzed by
repeated-measures analysis of co-
variance, with treatment, day,
and treatment  day interaction
as independent variables; baseline
LDL-C as a covariate; and subject
as a random effect. Percentage
changes were calculated as inverses
of the ratios. Repeated-measures
analyses analogous to those for
LDL-C were done for all efficacy endpoints, and p values were
generated.
Results
Study population. In the phase 1a study, 56 healthy
subjects were randomized and received the investigational
product (AMG 145, n  42; placebo, n  14) (Fig. 2A).
Three AMG 145 subjects discontinued the study after
receiving the investigational product, all for personal reasons
and none because of AEs. In the phase 1b study, 57 subjects
were randomized, received AMG 145 (n  43) or placebo
(n  14), and completed the study; 3 subjects were
randomized but withdrew before receiving the investiga-
tional product (Fig. 2B). In both studies, baseline demo-
graphic data and disease characteristics were balanced over-
all between the AMG 145 and placebo groups (Table 1).
Effects of AMG 145 on lipids. Treatment with AMG 145
resulted in significant, dose-dependent reductions in
LDL-C in both studies (Fig. 3, Table 2). In the phase 1a
study, single doses of AMG 145 21 mg reduced mean
LDL-C levels by up to 64% compared with placebo
(p  0.0001). Minimal differences in the magnitude or
duration of LDL-C reduction were observed between
equivalent subcutaneous or intravenous doses. In the phase
1b study, AMG 145 reduced mean LDL-C levels up to 81%
versus placebo (p  0.001) at nadir and by up to 75% versus
placebo (p  0.001) at the end of the dosing interval. The
LDL-C reductions in the high-dose statin and HeFH
cohorts were comparable to those in the dose-matched low-
to moderate-dose statin cohort (Table 2).
AMG 145 treatment also resulted in significant dose-
Abbreviations
and Acronyms
AE  adverse event
ApoB  apolipoprotein B
CK  creatine kinase
HDL-C  high-density
lipoprotein cholesterol
HeFH  heterozygous
familial
hypercholesterolemia
LDL-C  low-density
lipoprotein cholesterol
LDL-R  low-density
lipoprotein receptor
Lp(a)  lipoprotein (a)
PCSK9  proprotein
convertase subtilisin/kexin
type 9
QW  weekly
Q2W  every 2 weeks
Q4W  every 4 weeksdependent reductions in ApoB versus placebo in both the
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AMG 145 Effects on LDL-C, Safety, and Tolerability November 6, 2012:1888–98phase 1a and 1b studies, up to 55% (p  0.0001) and 59% (p
 0.001), respectively (Fig. 4, Table 2). In the phase 1b study,
ApoB reductions in the high-dose statin and HeFH cohorts
were similar to those in the dose-matched low- to moderate-
dose statin cohort (Table 2). Treatment with AMG 145 in
phase 1b reduced mean serum levels of Lp(a) by 27% (35 mg
QW 6, p 0.033) to 50% (HeFH cohort 140 mg Q2W
3, p  0.001) versus placebo at the end of the dosing interval
(Fig. 4, Table 2). Significant, dose-related reductions in total
cholesterol were also observed in both studies (Table 2). As
expected, no treatment effects were observed on HDL-C or
triglyceride levels (data not shown).
AMG 145 significantly reduced free PCSK9 levels in both
studies; the magnitude and duration of PCSK9 reductions influ-
Figure 1 Study Design
AMG 145 was evaluated in 2 randomized, double-blind, placebo-controlled ascend
IV  intravenous; QW  weekly; Q2W  every 2 weeks; Q4W  every 4 weeks; Senced the extent and duration of LDL-C reductions (Fig. 5). In
the phase 1b study, PCSK9 reductions in the high-dose statin and
HeFH cohorts were similar to those in the dose-matched low- to
moderate-dose statin cohort (data not shown).
Safety, tolerability, and immunogenicity. Key safety data
for both studies are summarized in Table 3. The overall
incidence of treatment-emergent AEs was similar between
the AMG 145 and placebo groups (Table 3). No serious
AEs or AEs leading to discontinuation occurred during
either study. No clinically important effects of AMG 145
were observed on selected laboratory parameters, electrocar-
diograms, or vital signs. No neutralizing antibodies to
AMG 145 were detected during either study. AEs consid-
ered treatment-related by the investigator were reported in
e phase 1 studies. HeFH  heterozygous familial hypercholesterolemia;
ubcutaneous.ing-dos
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November 6, 2012:1888–98 AMG 145 Effects on LDL-C, Safety, and Tolerability43% of AMG 145 subjects and 71% of placebo subjects in
the phase 1a study and in 23% of AMG 145 subjects and
14% of placebo subjects in phase 1b.
One case of myositis was reported as an AE in each of 3
phase 1a subjects (7%, AMG 145). One event was reported
as treatment-related; it was mild, occurred 21 days post-
dose concurrent with creatine kinase (CK) elevation2.5 to
 the upper limit of normal (ULN), and resolved 23 days
ost-dose. Two moderate, non-treatment-related events
ere reported in phase 1a; both events occurred more than
0 days after AMG 145 administration, after strenuous phys-
cal activity, and were associated with CK elevations (1 subject,
5 to 10 ULN; 1 subject, 10 ULN). In both cases, no
Figure 2 Subject Disposition
Three subjects in each study discontinued the studies, none because of adverse envestigational product was detectable at the time of the event. bn phase 1a, the overall incidence of CK elevation reported as
n AE was 21% for AMG 145 and 14% for placebo (Table 3).
n phase 1b, no significant differences between AMG 145 and
lacebo were observed in the incidence of treatment-emergent
Es of potential clinical importance. Two phase 1b subjects
eceiving AMG 145 (1 each in the high-dose statin and HeFH
ohorts) had grade 3 CK elevations after strenuous physical
ctivity.
iscussion
n 2 randomized, placebo-controlled, phase 1 ascending-
ose studies, AMG 145—a fully human monoclonal anti-
. Abbreviations as in Figure 1.ventsody to PCSK9—significantly lowered serum LDL-C
1
h
Q
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Healthy Subjects (Phase 1a)
Characteristic at
Baseline
AMG 145
All Placebo
(n  14)
7 mg SC
(n  6)
21 mg SC
(n  6)
70 mg SC
(n  6)
210 mg SC
(n  6)
420 mg SC
(n  6)
21 mg IV
(n  6)
420 mg IV
(n  6)
All AMG 145
(n  42)
Men 6 (100) 6 (100) 6 (100) 6 (100) 6 (100) 5 (83) 6 (100) 41 (98) 13 (93)
Age, yrs 36 7 25 6 33 9 28 5 31 9 31 9 35 6 31 8 31 9
Body mass index,
kg/m2
26 3 25 3 24 3 25 3 27 2 27 2 27 3 26 3 26 3
Free PCSK9,
ng/ml
320 101 234 17 258 83 253 49 303 40 219 28 301 42 270 65 265 48
LDL-C, mg/dl 132 26 120 22 118 20 123 26 143 25 116 12 132 14 126 22 113 13
Total cholesterol,
mg/dl
213 34 202 25 178 21 186 29 223 38 188 11 208 23 200 29 188 26
HDL-C, mg/dl 54 16 52 6 51 11 43 5 58 22 52 6 46 11 51 12 47 15
ApoB, g/l 1.0 0.1 0.9 0.2 0.9 0.1 0.9 0.2 1.0 0.2 0.8 0.1 1.0 0.1 0.9 0.2 0.9 0.2
Triglycerides,
mg/dl
114 (76, 292) 117 (90, 156) 92 (37, 231) 122 (80, 164) 135 (84, 322) 95 (55, 225) 129 (102, 154) 114 (37, 322) 134 (76, 385)
Subjects With Hypercholesterolemia (Phase 1b)
AMG 145*
All Placebo*
(n  14)
Low- to Moderate-Dose Statins, Non-HeFH High-Dose
Statins
140 mg Q2W
(3 doses)
(n  9)
HeFH
140 mg Q2W
(3 doses)
(n  4)
All AMG 145
(n  43)
14 mg QW
(6 doses)
(n  6)
35 mg QW
(6 doses)
(n  6)
140 mg Q2W
(3 doses)
(n  6)
280 mg Q2W
(3 doses)
(n  6)
420 mg Q4W
(2 doses)
(n  6)
Men† 2 (33) 5 (83) 3 (50) 2 (33) 3 (50) 6 (67) 4 (100) 25 (58) 6 (43)
Age, yrs 61 4 64 6 56 7 56 9 54 5 58 8 45 15 57 9 57 7
Body mass index, kg/m2 26 3 30 3 30 4 25 2 29 3 28 3 29 5 28 3 28 2
Free PCSK9, ng/ml 491 158 400 117 385 88 374 96 459 163 487 214 396 86 433 146 429 89
LDL-C, mg/dl 127 22 107 29 114 15 106 17 120 33 100 26 135 31 113 26 116 34
Total cholesterol, mg/dl 209 12 178 27 189 27 172 24 197 48 171 36 188 27 185 32 186 37
HDL-C, mg/dl 59 8 50 8 55 13 56 14 55 14 49 14 41 4 53 12 57 16
ApoB, g/l 1.0 0.1 0.9 0.2 1.0 0.2 0.8 0.1 1.0 0.2 0.9 0.1 0.9 0.2 0.9 0.2 1.0 0.2
Triglycerides mg/dl 134 (69, 184) 125 (92, 252) 158 (74, 547) 80 (61, 137) 126 (111, 225) 108 (57, 299) 73 (52, 201) 117 (52, 547) 98 (44, 244)
Lp(a), nmol/l‡ (n  3)
159 (120, 281)
(n  4)
35 (17, 281)
(n  4)
128 (47, 243)
(n  2)
44 (42, 47)
(n  5)
35 (13, 171)
(n  8)
57 (21, 345)
(n  3)
31 (18, 108)
(n  29)
50 (13, 345)
(n  13)
125 (14, 470)
Statin use
Atorvastatin
40 mg 1 (17) 2 (33) 1 (17) 4 (67) 2 (33) 0 (0) 2 (50) 12 (28) 4 (29)
80 mg 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 3 (33) 0 (0) 3 (7) 2 (14)
Rosuvastatin
20 mg 1 (17) 1 (17) 1 (17) 0 (0) 3 (50) 0 (0) 0 (0) 6 (14) 4 (29)
40 mg 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 6 (67) 1 (25) 7 (16) 1 (7)
Simvastatin
40 mg 1 (17) 3 (50) 3 (50) 2 (33) 1 (17) 0 (0) 1 (25)§ 11 (26)§ 3 (21)
80 mg 3 (50) 0 (0) 1 (17) 0 (0) 0 (0) 0 (0) 0 (0) 4 (9) 0 (0)
Values are n (%), mean  SD, or median (min, max). *In the study of hypercholesterolemic subjects (phase 1b), all doses of AMG 145 and placebo were subcutaneous (SC). †Percentages might not equal
00%, because of rounding. ‡The analysis excluded subjects with screening or baseline lipoprotein (Lp)(a) values below the level of quantification and one subject whose baseline value seemed implausibly
igh compared with post-baseline values. §One subject in the heterozygous familial hypercholesterolemia (HeFH) AMG 145 cohort was receiving simvastatin 40 mg/ezetimibe 10 mg.
ApoB apolipoprotein B; HDL-C high-density lipoprotein cholesterol; IV intravenous; LDL-C low-density lipoprotein cholesterol; PCSK9 proprotein convertase subtilisin/kexin type 9; QWweekly;
2W  every 2 weeks; Q4W  every 4 weeks.
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November 6, 2012:1888–98 AMG 145 Effects on LDL-C, Safety, and Tolerabilitylevels compared with placebo in healthy subjects and in
subjects with or without HeFH who were receiving stable
statin therapy. The reductions in LDL-C, driven by dose-
dependent reductions in free PCSK9, were rapid, dose-
related, and consistent across cohorts. The LDL-C reduc-
tion seemed to be independent of statin type or dose and
was consistent with results recently reported in 2 studies
using another PCSK9 antibody, REGN727/SAR236553
(17,18). In contrast to the reported results with REGN727/
SAR236553 at a high dose (6), Q4W dosing with 420 mg
AMG 145 in this study showed sustained reductions
(60%) over the 4-week dosing interval. AMG 145 also
significantly reduced ApoB and Lp(a) versus placebo.
Statins are associated with an increase in PCSK9
(11–14), which might theoretically impact the duration
Figure 3 Mean Percentage Change From Baseline in LDL-C
(A) Healthy subjects. (B) Subjects with hypercholesterolemia receiving low- to mod
(D) Subjects with HeFH. LDL-C  low-density lipoprotein cholesterol; other abbreviof effect with AMG 145 due to increased PCSK9synthesis and faster antibody clearance. However, the
magnitude and duration of LDL-C lowering observed in
the cohort receiving the highest doses of atorvastatin or
rosuvastatin were comparable to those of subjects receiv-
ing lower statin doses after 3 biweekly 140-mg doses of
AMG 145.
Robust and sustained reductions in Lp(a) were observed
in this study, consistent with those reported for REGN727/
SAR236553 (17,18). Lp(a), an LDL-like particle contain-
ing an ApoB molecule linked to apolipoprotein (a), is
associated with an increased independent risk of coronary
heart disease and stroke (19). Other LDL-C-lowering
agents that up-regulate LDL-R activity show no effect on
Lp(a); thus, the mechanism of Lp(a) reduction with AMG
145 warrants further exploration. The safety and tolerability
dose statins. (C) Subjects with hypercholesterolemia receiving high-dose statins.
as in Figure 1.erate-
ationsprofile of AMG 145 was similar to that of placebo, and
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AMG 145 Effects on LDL-C, Safety, and Tolerability November 6, 2012:1888–98AMG 145 on Lipids: Mean Percentage ChangeTable 2 AMG 145 on Lipids: Mean Percentage Change
Healthy Subjects (Phase 1a): Change From Baseline at Nadir
Parameter
AMG 145
Placebo
(n  14)
7 mg SC
(n  6)
21 mg SC
(n  6)
70 mg SC
(n  6)
210 mg SC
(n  6)
420 mg SC
(n  6)
21 mg IV
(n  6)
420 mg IV
(n  6)
LDL-C
Change from baseline, mean 10% 37% 55% 55% 67% 42% 63% 9%
Time to nadir, days 7 6 11 15 22 5 22
Change vs. placebo, mean 6% 31% 53% 53% 64% 38% 61%
Time to nadir, days 4 5 11 15 22 5 22
p value, change vs. placebo 0.4412 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001
Total cholesterol
Change from baseline, mean 10% 29% 38% 40% 44% 28% 47% 10%
Time to nadir, days 8 5 11 15 22 5 22
Change vs. placebo, mean 3% 21% 32% 36% 40% 21% 43%
Time to nadir, days 4 5 11 15 15 5 22
p value, change vs. placebo 0.5287 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001
ApoB
Change from baseline, mean 16% 31% 48% 49% 57% 34% 56% 15%
Time to nadir, days 8 5 11 15 22 5 22
Change vs. placebo, mean 6% 25% 42% 45% 55% 28% 53%
Time to nadir, days 8 5 11 15 22 5 22
p value, change vs. placebo 0.3446 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001
Subjects With Hypercholesterolemia (Phase 1b): Mean Percentage Change at End of Dosing Interval* and Mean Maximum Change
Parameter
AMG 145†
Placebo†
(n  14)
Low- to Moderate-Dose Statins, Non-HeFH High-Dose
Statins
140 mg Q2W
(3 doses)
(n  9)
HeFH
140 mg Q2W
(3 doses)
(n  4)
14 mg QW
(6 doses)
(n  6)
35 mg QW
(6 doses)
(n  6)
140 mg Q2W
(3 doses)
(n  6)
280 mg Q2W
(3 doses)
(n  6)
420 mg Q4W
(2 doses)
(n  6)
LDL-C
End of the dosing interval
Change from baseline, mean 24% 55% 73% 75% 63% 65% 66% 2%
Change vs. placebo, mean 22% 54% 73% 75% 66% 63% 65%
p value, change vs. placebo 0.14 0.001 0.001 0.001 0.001 0.001 0.001
Maximum reduction at nadir
Change from baseline, mean 31% 61% 81% 75% 79% 78% 73% 5%
Change vs. placebo, mean 34% 60% 81% 76% 80% 77% 70%
p value, change vs. placebo 0.015 0.001 0.001 0.001 0.001 0.001 0.001
Total cholesterol
End of the dosing interval
Change from baseline, mean 15% 35% 46% 41% 41% 36% 41% 2%
Change vs. placebo, mean 14% 34% 45% 40% 45% 35% 42%
p value, change vs. placebo 0.058 0.001 0.001 0.001 0.001 0.001 0.001
Maximum reduction
Change from baseline, mean 21% 38% 49% 42% 52% 50% 49% 2%
Change vs. placebo, mean 20% 37% 50% 42% 52% 49% 47%
p value, change vs. placebo 0.006 0.001 0.001 0.001 0.001 0.001 0.001Continued on next page
th post
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AEs.
In summary, AMG 145 provided robust, significant
reductions in plasma LDL-C levels versus placebo in
different groups of hypercholesterolemic subjects with both
Q2W and Q4W doses. The overall AE profiles were similar
between AMG 145 and placebo groups. Treatment with
AMG 145 may provide substantial LDL-C-lowering ben-
efits in patients who do not respond adequately to statins or
who cannot meet their LDL-C reduction goals on the
highest doses of atorvastatin and rosuvastatin. Phase 2
studies building upon this foundation are in progress.
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Subjects With Hypercholesterolemia (Phase 1b): Mean Percent
Parameter
Low- to Moderate-Dose S
14 mg QW
(6 doses)
(n  6)
35 mg QW
(6 doses)
(n  6)
140 mg Q2W
(3 doses)
(n  6)
ApoB
End of the dosing interval
Change from baseline, mean 19% 46% 53%
Change vs. placebo, mean 15% 43% 51%
p value, change vs. placebo 0.096 0.001 0.001
Maximum reduction at nadir
Change from baseline, mean 25% 48% 58%
Change vs. placebo, mean 25% 48% 59%
p value, change vs. placebo 0.004 0.001 0.001
Lp(a)‡ n  3 n  4 n  4
End of the dosing interval
Change from baseline, mean 20% 30% 33%
Change vs. placebo, mean 16% 27% 30%
p value, change vs. placebo 0.28 0.033 0.016
Maximum reduction at nadir
Change from baseline, mean 25% 38% 33%
Change vs. placebo, mean 18% 31% 30%
p value, change vs. placebo 0.21 0.011 0.016
Data from subjects who withdrew early were excluded. *The end of the dosing interval was day 43 fo
subjects (phase 1b), all doses of AMG 145 and placebo were SC. ‡The Lp(a) level was measured o
level of quantification and 1 subject whose baseline value seemed implausibly high compared wi
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November 6, 2012:1888–98 AMG 145 Effects on LDL-C, Safety, and TolerabilityFigure 5 Mean Percentage Change From Baseline in Free PCSK9
(A) Healthy subjects. (B) Subjects with hypercholesterolemia receiving low- to moderate-dose statins. PCSK9  proprotein convertase subtilisin/kexin type 9; other
abbreviations as in Figure 1.Subject Incidence of AEsTable 3 Subject Incidence of AEs
Healthy Subjects (Phase 1a)
AMG 145
Placebo
(n  14)
7 mg SC
(n  6)
21 mg SC
(n  6)
70 mg SC
(n  6)
210 mg SC
(n  6)
420 mg SC
(n  6)
21 mg IV
(n  6)
420 mg IV
(n  6)
All AMG 145
(n  42)
Subjects reporting treatment-emergent AEs 3 (50) 4 (67) 4 (67) 2 (33) 6 (100) 5 (83) 5 (83) 29 (69) 10 (71)
Subjects reporting AEs considered
treatment-related by the investigator
2 (33) 3 (50) 4 (67) 2 (33) 1 (17) 4 (67) 2 (33) 18 (43) 10 (71)
Subjects reporting serious AEs 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Discontinuations due to AEs 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Deaths on study 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Treatment-emergent AEs reported in 3 or
more subjects overall*
Increased CK 0 (0) 1 (17) 0 (0) 1 (17) 3 (50) 0 (0) 4 (67) 9 (21) 2 (14)
Pharyngitis 0 (0) 1 (17) 2 (33) 0 (0) 1 (17) 3 (50) 0 (0) 7 (17) 1 (7)
Cough 1 (17) 0 (0) 2 (33) 0 (0) 0 (0) 0 (0) 1 (17) 4 (10) 3 (21)
Upper respiratory tract infection 0 (0) 0 (0) 1 (17) 0 (0) 1 (17) 0 (0) 1 (17) 3 (7) 2 (14)Continued on next page
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AMG 145 Effects on LDL-C, Safety, and Tolerability November 6, 2012:1888–9817. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC,
Stein EA. Safety and efficacy of a monoclonal antibody to proprotein
convertase subtilisin/kexin type 9 serine protease, SAR236553/
REGN727, in patients with primary hypercholesterolemia receiving
ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012;59:2344–
353.
18. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal
ContinuedTable 3 Continued
Healthy Sub
7 mg SC
(n  6)
21 mg SC
(n  6)
70 mg S
(n  6
Myositis 0 (0) 1 (17) 0 (0)
Nasal congestion 0 (0) 0 (0) 0 (0)
Diarrhea 0 (0) 0 (0) 0 (0)
Oropharyngeal pain 1 (17) 0 (0) 0 (0)
Subjects With Hyperc
Low- to Moderate-Dose Sta
14 mg QW
(6 doses)
(n  6)
35 mg QW
(6 doses)
(n  6)
140 mg
Q2W
(3 doses)
(n  6)
Subjects reporting treatment-emergent AEs 2 (33) 5 (83) 4 (67)
Subjects reporting AEs considered
treatment-related by the investigator
1 (17) 0 (0) 1 (17)
Subjects reporting serious AEs 0 (0) 0 (0) 0 (0)
Discontinuations due to AEs 0 (0) 0 (0) 0 (0)
Deaths on study 0 (0) 0 (0) 0 (0)
Treatment-emergent AEs reported in 3 or
more subjects overall*
Nasopharyngitis 0 (0) 1 (17) 1 (17)
Injection-site hematoma 0 (0) 0 (0) 0 (0)
Viral upper respiratory tract infection 0 (0) 1 (17) 1 (17)
Values are n (%). *Adverse events (AEs) listed occurred in3 of all subjects overall who received a
all doses of AMG 145 and placebo were SC.
AE  adverse event; CK  creatine kinase; other abbreviations as in Table 1.antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012;366:
1108–18.19. Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and
the risk of coronary heart disease, stroke, and nonvascular mortality.
JAMA 2009;302:412–23.
Key Words: hypercholesterolemia y LDL-C y PCSK9.
APPENDIX
(Phase 1a)
AMG 145
Placebo
(n  14)
10 mg SC
(n  6)
420 mg SC
(n  6)
21 mg IV
(n  6)
420 mg IV
(n  6)
All AMG 145
(n  42)
0 (0) 1 (17) 0 (0) 1 (17) 3 (7) 0 (0)
0 (0) 1 (17) 1 (17) 0 (0) 2 (5) 2 (14)
0 (0) 1 (17) 1 (17) 0 (0) 2 (5) 1 (7)
0 (0) 0 (0) 0 (0) 0 (0) 1 (2) 2 (14)
erolemia (Phase 1b)
AMG 145†
Placebo†
(n  14)
on-HeFH
High-Dose Statins
140 mg Q2W
(3 doses)
(n  9)
HeFH
140 mg Q2W
(3 doses)
(n  4)
All AMG 145
(n  43)
mg
W
ses)
6)
420 mg
Q4W
(2 doses)
(n  6)
00) 3 (50) 7 (78) 1 (25) 28 (65) 9 (64)
00) 0 (0) 2 (22) 0 (0) 10 (23) 2 (14)
) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
7) 0 (0) 0 (0) 0 (0) 3 (7) 1 (7)
7) 0 (0) 1 (11) 0 (0) 2 (5) 2 (14)
) 0 (0) 0 (0) 0 (0) 2 (5) 1 (7)
SC or IV dose of AMG 145 or placebo. †In the study of hypercholesterolemic subjects (phase 1b),jects
C
)
2
holest
tins, N
280
Q2
(3 do
(n 
6 (1
6 (1
0 (0
0 (0
0 (0
1 (1
1 (1
0 (0
t least 1For additional information, please see the online version of this article.
